Department of Orthopedic Surgery, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang 471009, China.
Immunotherapy. 2020 Jun;12(9):641-652. doi: 10.2217/imt-2020-0107. Epub 2020 Jun 3.
To investigate the efficacy of adjuvant chemotherapy plus tumor-infiltrating lymphocytes (TILs) therapy in osteosarcoma patients with a poor response to neoadjuvant chemotherapy. 40 patients received adjuvant chemotherapy (Group 1) and 40 patients received adjuvant chemotherapy plus TILs therapy (Group 2). Disease-free survival (DFS) and overall survival (OS) were analyzed by Kaplan-Meier analysis. The median DFS (mDFS; 65.3 months) and median OS (mOS; 95.8 months) in Group 2 were significantly prolonged compared with those in Group 1 (55.5 months for mDFS and 80.4 months for mOS). Univariate and multivariate analyses indicated that a greater number of TILs transfused was an independent prognostic factor for both mDFS and mOS. Adjuvant chemotherapy plus TILs therapy may prolong survival of patients with a poor response to neoadjuvant chemotherapy.
探讨辅助化疗联合肿瘤浸润淋巴细胞（TIL）治疗对新辅助化疗反应不佳的骨肉瘤患者的疗效。40 例患者接受辅助化疗（组 1），40 例患者接受辅助化疗加 TIL 治疗（组 2）。采用 Kaplan-Meier 分析分析无病生存（DFS）和总生存（OS）。与组 1（mDFS 为 55.5 个月，mOS 为 80.4 个月）相比，组 2 的中位 DFS（mDFS；65.3 个月）和中位 OS（mOS；95.8 个月）显著延长。单因素和多因素分析表明，输注的 TIL 数量较多是 mDFS 和 mOS 的独立预后因素。辅助化疗联合 TIL 治疗可能延长新辅助化疗反应不佳患者的生存时间。
